Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus CEFTRIAXONE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus CEFTRIAXONE IN PLASTIC CONTAINER.
CEFADYL vs CEFTRIAXONE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic